Meta-analysis of tumor mutation burden predicting the efficacy of immune checkpoint inhibitors in patients with gastrointestinal malignancies
LAI Xiangli
CHEN Zhixin
SHEN Yongqi
QIN Junyun
LIN Deshuai
LIU Jin'e
MO Que
HAN Chaowen
Abstract：Objective To systematically evaluate the value of tumor mutation burden(TMB)predicting the efficacy of immune checkpoint inhibitors(ICIs)in patients with gastrointestinal malignancies.Methods A total of 963 papers of the relevant literature in PubMed,Web of Science and Cochrane Library databases from the time of establishment to December 1 2021 were searched,and 12 papers of the relevant literature(including 1 126 cases of gastrointestinal malig-nancies treated with ICIs)were finally included for Meta-analysis.The main evaluation indicators included objective response rate(ORR),progression-free survival(PFS),and overall survival(OS).Results In the patients treated with ICIs,the patients with high TMB had longer OS[HR(95％CI)=0.71(0.51-0.97),P=0.031],and higher ORR[OR(95％CI)=4.22(2.58-6.90),P＜0.001]compared with those with low TMB.However,there was no significant difference in PFS between the two group of the patients[HR(95％CI)=0.77(0.48-1.23),P=0.276].Conclusion The gastrointestinal malignancy patients with high TMB are more likely to benefit from the treatment of ICIs.
Keywords：Tumor mutation burden(TMB)Gastrointestinal malignancyImmune checkpoint inhibitors(ICIs)Meta-analysis
Publication Date：2024-08-28
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：7( 913-919 )